About Harbour Antibodies
Harbour Antibodies is a company based in Rotterdam (Netherlands) founded in 2006 was acquired by Harbour BioMed in December 2016.. Harbour Antibodies has raised $3.3 million across 2 funding rounds from investors including Harbour BioMed, European Union and Atlas Venture. Harbour Antibodies offers products and services including H2L2 and HCAB. Harbour Antibodies operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Rotterdam, Netherlands
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Harbour Antibodies Bv
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3.3 M (USD)
in 2 rounds
-
Latest Funding Round
$110.52 K (USD), Grant
Mar 01, 2020
-
Investors
Harbour BioMed
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Harbour BioMed
(Dec 19, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Harbour Antibodies
Harbour Antibodies offers a comprehensive portfolio of products and services, including H2L2 and HCAB. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Transgenic mouse for generating fully human IgG antibodies.
Platform for heavy chain only monoclonal antibodies.
Funding Insights of Harbour Antibodies
Harbour Antibodies has successfully raised a total of $3.3M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $110.52 thousand completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $110,520
-
First Round
First Round
(24 Jul 2013)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2020 | Amount | Grant - Harbour Antibodies | Valuation |
investors |
|
| Jul, 2013 | Amount | Series A - Harbour Antibodies | Valuation | Atlas Venture |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Harbour Antibodies
Harbour Antibodies has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Harbour BioMed, European Union and Atlas Venture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Antibody therapeutics are developed for immunology and oncology diseases.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Harbour Antibodies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Harbour Antibodies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Harbour Antibodies Comparisons
Competitors of Harbour Antibodies
Harbour Antibodies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Harbour Antibodies
Frequently Asked Questions about Harbour Antibodies
When was Harbour Antibodies founded?
Harbour Antibodies was founded in 2006 and raised its 1st funding round 7 years after it was founded.
Where is Harbour Antibodies located?
Harbour Antibodies is headquartered in Rotterdam, Netherlands. It is registered at Rotterdam, South Holland, Netherlands.
Is Harbour Antibodies a funded company?
Harbour Antibodies is a funded company, having raised a total of $3.3M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.3M, raised on Jul 24, 2013.
What does Harbour Antibodies do?
Harbour Antibodies was founded in 2006 in Rotterdam, Netherlands, within the biotechnology sector. Transgenic mouse platforms have been developed to produce fully human antibodies, including conventional tetrameric forms with heavy and light chains, as well as heavy-chain-only antibodies without light chains. These platforms are licensed to pharmaceutical and biotech partners for antibody-based therapeutic development. Operations focus on enabling diverse antibody generation for therapeutic applications.
Who are the top competitors of Harbour Antibodies?
Harbour Antibodies's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Harbour Antibodies offer?
Harbour Antibodies offers H2L2 and HCAB.
Who are Harbour Antibodies's investors?
Harbour Antibodies has 3 investors. Key investors include Harbour BioMed, European Union, and Atlas Venture.